Dec 15 (Reuters) - Ontex Group NV ONTEX.BR :-
* ONTEX TO FOCUS ON PARTNER BRANDS & HEALTHCARE IN EUROPE
AND
NORTH AMERICA, MARKING A STRATEGY SHIFT TOWARDS CREATION OF A
NEW ONTEX
* DIVESTMENTS, EXTENDED COST PROGRAM AND COST-DRIVEN PRICING
EXPECTED TO BRING 2023 TARGETS FOR CORE BUSINESS INTO REACH,
DESPITE CURRENT UNPRECEDENTED INPUT COST INFLATION
* 2021 OUTLOOK AFFECTED BY SUPPLY DISRUPTIONS
* DIVESTMENTS, EXTENDED COST PROGRAM AND COST-DRIVEN PRICING
BRING
2023 TARGETS FOR CORE BUSINESS INTO REACH, DESPITE CURRENT
UNPRECEDENTED INPUT COST INFLATION
* +2-3% LIKE-FOR-LIKE REVENUE GROWTH AND ADJUSTED EBITDA
MARGINS
OF 12.5%-13.5% BY END 2023, FOR ONTEX CORE BUSINESS
* PROCEEDS FROM DIVESTMENTS, WORKING CAPITAL & CAPITAL
EXPENDITURE
DISCIPLINE TO LEAD TO AN IMPROVEMENT OF ONTEX'S LEVERAGE RATIO,
WITH NET DEBT BELOW 3X ADJUSTED EBITDA, BY END 2023
* DISRUPTION IN SUPPLY CONTINUED AND ANTICIPATED IMPROVEMENT
IN Q4
HAS BEEN SLOWER THAN ORIGINALLY ANTICIPATED. THIS UNEXPECTED
SETBACK IMPACTS ONTEX'S PREVIOUS OUTLOOK OF -1% LIKE-FOR-LIKE
REVENUE DECREASE AND 9% ADJUSTED EBITDA MARGIN FOR YEA
* ONTEX NOW EXPECTS BOTH REVENUE GROWTH AND ADJUSTED EBITDA
MARGIN
TO COME OUT APPROXIMATELY 0.5 POINTS LOWER THAN PREVIOUS OUTLOOK
* 2021 CAPITAL EXPENDITURE IS ANTICIPATED TO BE BELOW 3.5%
OF
SALES
Source text for Eikon: ID:nBwbBmYxca
Further company coverage: ONTEX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))